Announcements
盛德助力和誉医药与礼来公司达成19亿美元战略合作
July 2, 2026
盛德代表和誉医药(Abbisko Therapeutics),与礼来公司(Eli Lilly and Company)达成新一轮战略研发合作与授权协议,以支持多个创新药项目的发现与早期开发工作。根据协议,和誉医药将发挥其药物发现与早期开发能力,推进礼来公司所选定的疾病靶点相关项目。此次合作包含一笔未披露金额的首付款,以及最高达19亿美元的潜在开发、监管和商业化里程碑付款,还有基于未来产品年度净销售额的分级销售分成。
盛德团队由 Joshua Hofheimer(技术与生命科学交易)带领,团队成员包括仇真、Karena Kong(技术与生命科学交易)及 Emily Marden(食品、药品与医疗器械)。
Contacts
*仇真有中国律师资格,但不持中国律师执业证。
Capabilities
Related Pages
Suggested News & Insights
Exclusive Fireside Chat: A Conversation With FDA's Chief CounselTuesday, January 12, 2027Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027GMP 2026: Regulatory Reliance, AI, and the Future of Pharmaceutical ManufacturingWednesday, December 2, 2026Sidley Represents Dechra in Acquisition of Gallant PetNovember 18, 2026Sidley Represents Sino Biopharmaceutical in its US$7 Billion Licensing Agreement With Boehringer IngelheimNovember 9, 2026Sidley Celebrated as the “Law Firm of the Year” in Two Areas by Best Lawyers: FDA Law and Securities RegulationNovember 5, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


